Clinical Biospecimen Collection
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Cancer Risk. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
New York Cancer and Blood Specialists: Clinical Biospecimen Collection for Research Use
Overview
New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.
Detailed description
Research and development of new diagnostics for earlier detection of, and new treatments for diseases require the use of human biological specimens (biospecimens). Through data and insight gained from the evaluation of these collected biospecimens, the aforementioned novel diagnostics and/or treatments can be developed or validated for a variety of diseases. Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
The samples and data may be used for genetic research such as: RNA or DNA isolation and analysis, gene and protein expression, diagnostic device and biomarker research, tissue microarray development, laboratory tests and validation tests. The biospecimens may also be used for genome sequencing.
Primary outcome measures
- Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals. [Time frame: 10 years]
Eligibility criteria
Inclusion criteria
- Subjects must be at least 18 years of age
- Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
- Subjects may or may not have active disease at the time of enrollment
- Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.
Exclusion criteria
4\) Subjects not meeting the inclusion criteria
Additional inclusion and exclusion criteria may exist, specific to individual project plans, for each collection falling under this protocol. These criteria may include genetic mutation status, progression of disease, and prior lines of therapy among others.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Other
Study locations
United States · 1 center
- NYCBS — Shirley
Identifiers
NCT: NCT07543159 · WCG Protocol #20253750